Jeff Chiprin - 11 Dec 2025 Form 4 Insider Report for IRADIMED CORP (IRMD)

Reporting relationship: Chief Commercial Officer
Issuer ticker: IRMD
Reported as of: 11 Dec 2025
Net transaction value: -$30,090
SEC form: 4
Accepted by SEC: 12 Dec 2025, 17:00:21 UTC
Prior SEC filing: 13 Dec 2024
Next SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeff Chiprin

Key filing fact

Jeff Chiprin filed Form 4 for IRADIMED CORP (IRMD) on 12 Dec 2025.

Key facts

This page summarizes Jeff Chiprin's Form 4 filing for IRADIMED CORP (IRMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Dec 2025, 17:00.

Change

Previous filing in this sequence was filed on 13 Dec 2024.
Current net transaction value: -$30,090.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002047489 Primary reporting owner

Chiprin Jeff

Relationship: Chief Commercial Officer
Address: C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO
Signature: /s/ Jeff Chiprin
Signature date: 12 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +996
Change %
Price
Shares after: 996
Date: 11 Dec 2025
Ownership: Direct
Footnotes: F1

IRMD transaction

Common Stock

Tax liability

Transaction value: $30,090
Shares: -309
Change %: -31%
Price: $97.38
Shares after: 687
Date: 11 Dec 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRMD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -996
Change %: -33%
Price: $0.000000
Shares after: 1,994
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 996
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.